433 related articles for article (PubMed ID: 27764794)
21. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
22. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression.
Lenhart R; Kirov S; Desilva H; Cao J; Lei M; Johnston K; Peterson R; Schweizer L; Purandare A; Ross-Macdonald P; Fairchild C; Wong T; Wee S
Mol Cancer Ther; 2015 Oct; 14(10):2167-74. PubMed ID: 26253517
[TBL] [Abstract][Full Text] [Related]
24. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
25. Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity.
Orihara H; Ma M; Nagashima Y; Tochinai R; Sekizawa SI; Kato D; Shinada M; Aoki S; Fujita N; Nakagawa T; Tsuru Y; Tatewaki Y; Mutoh T; Taki Y; Nishimura R; Kuwahara M
Biomed Pharmacother; 2023 Apr; 160():114353. PubMed ID: 36736274
[TBL] [Abstract][Full Text] [Related]
26. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
27. Bromodomain and extraterminal proteins suppress NF-E2-related factor 2-mediated antioxidant gene expression.
Michaeloudes C; Mercado N; Clarke C; Bhavsar PK; Adcock IM; Barnes PJ; Chung KF
J Immunol; 2014 May; 192(10):4913-4920. PubMed ID: 24733848
[TBL] [Abstract][Full Text] [Related]
28. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
29. Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1.
Decker TM; Kluge M; Krebs S; Shah N; Blum H; Friedel CC; Eick D
Sci Rep; 2017 May; 7(1):1684. PubMed ID: 28490802
[TBL] [Abstract][Full Text] [Related]
30. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
31. GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1.
Kumar K; Raza SS; Knab LM; Chow CR; Kwok B; Bentrem DJ; Popovic R; Ebine K; Licht JD; Munshi HG
Sci Rep; 2015 Mar; 5():9489. PubMed ID: 25807524
[TBL] [Abstract][Full Text] [Related]
32. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1.
Stewart HJ; Horne GA; Bastow S; Chevassut TJ
Cancer Med; 2013 Dec; 2(6):826-35. PubMed ID: 24403256
[TBL] [Abstract][Full Text] [Related]
33. The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
Lei L; Xie X; He L; Chen K; Lv Z; Zhou B; Li Y; Hu W; Zhou Z
Invest New Drugs; 2021 Apr; 39(2):362-376. PubMed ID: 32981006
[TBL] [Abstract][Full Text] [Related]
34. MCM5 as a target of BET inhibitors in thyroid cancer cells.
Mio C; Lavarone E; Conzatti K; Baldan F; Toffoletto B; Puppin C; Filetti S; Durante C; Russo D; Orlacchio A; Di Cristofano A; Di Loreto C; Damante G
Endocr Relat Cancer; 2016 Apr; 23(4):335-47. PubMed ID: 26911376
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
36. The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.
Jostes S; Nettersheim D; Fellermeyer M; Schneider S; Hafezi F; Honecker F; Schumacher V; Geyer M; Kristiansen G; Schorle H
J Cell Mol Med; 2017 Jul; 21(7):1300-1314. PubMed ID: 28026145
[TBL] [Abstract][Full Text] [Related]
37. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer.
Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A
Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213
[TBL] [Abstract][Full Text] [Related]
38. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo.
Kumar K; DeCant BT; Grippo PJ; Hwang RF; Bentrem DJ; Ebine K; Munshi HG
JCI Insight; 2017 Feb; 2(3):e88032. PubMed ID: 28194432
[TBL] [Abstract][Full Text] [Related]
39. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
40. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]